Cerus' INTERCEPT Plasma Granted Orphan Drug Designation For Treatment Of Thrombotic Thrombocytopenic Purpura (TTP)
Links shared publicly online about this topic.
- 493total visits
Cerus' INTERCEPT Plasma Granted Orphan Drug Designation For Treatment Of Thrombotic Thrombocytopenic Purpura (TTP)
Cerus Corporation (NASDAQ:CERS) announced that it has been granted orphan drug status for plasma prepared with the INTERCEPT Blood System for treatment of thrombotic thrombocytopenic purpura (TTP)
View full resource at medicalnewstoday.com
Tags: Platelet Disorder, Thrombotic Thrombocytopenic Purpura, Drug
Most Recently Shared on February 20, 2011 at 2:05 pm By:
Cerus' INTERCEPT Plasma Granted Orphan Drug Designation For Treatment Of Thrombotic Thrombocytopenic Purpura (TTP) http://mnt.to/3RmN
Also Shared By:
Advertisement
MNT Blood
@mnt_blood
Cerus' INTERCEPT Plasma Granted Orphan Drug Designation For Treatment Of Thrombotic Thrombocytopenic Purpura (TTP) http://mnt.to/3RmN
1 year ago...